Squarepoint
KZR

Squarepoint’s Kezar Life Sciences KZR Stock Holding History

Squarepoint’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,299
Closed -$99.1K – 4791
2025
Q1 		$99.1K Buy
+20,299
New +$123K ﹤0.01% 4223
2024
Q4 		– Sell
-9,850
Closed -$76.2K – 5293
2024
Q3 		$76.2K Buy
9,850
+5,766
+141% +$34.8K ﹤0.01% 3928
2024
Q2 		$24.5K Buy
+4,084
New +$31K ﹤0.01% 3951
2024
Q1 		– Sell
-18,671
Closed -$177K – 4318
2023
Q4 		$177K Buy
18,671
+3,378
+22% +$29.7K ﹤0.01% 3640
2023
Q3 		$182K Buy
+15,293
New +$271K ﹤0.01% 3440
2023
Q2 		– Sell
-29,538
Closed -$925K – 3803
2023
Q1 		$925K Buy
+29,538
New +$1.71M ﹤0.01% 1953
2022
Q3 		– Sell
-3,901
Closed -$323K – 3218
2022
Q2 		$323K Buy
3,901
+2,546
+188% +$225K ﹤0.01% 2258
2022
Q1 		$225K Sell
1,355
-3,479
-72% -$499K ﹤0.01% 2425
2021
Q4 		$808K Buy
+4,834
New +$546K ﹤0.01% 1829
2020
Q2 		– Sell
-3,623
Closed -$158K – 2384
2020
Q1 		$158K Buy
+3,623
New +$147K ﹤0.01% 1548

Other funds holding KZR

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Squarepoint's KZR Position: Q2 2025 in Review

Squarepoint sold out of Kezar Life Sciences (KZR) in Q2 2025, closing a stake of 20,299 shares — an estimated $99.1K sold.

Squarepoint first reported a position in KZR in Q1 2020 and held it in 10 quarters. The position peaked at $925K in Q1 2023. 40 funds tracked by Wall St. Rank hold KZR as of Q2 2025.

  • Squarepoint reported no remaining Kezar Life Sciences position as of Q2 2025 after selling out during the quarter.
  • Squarepoint sold 20,299 Kezar Life Sciences shares in Q2 2025, an estimated $99.1K.
  • Squarepoint first reported a position in Kezar Life Sciences in Q1 2020 and held it in 10 quarters.
  • Squarepoint's Kezar Life Sciences position peaked at $925K in Q1 2023.
  • 40 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.